Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry

被引：0
|
作者：
George, Tracy I. [1 ,2 ]
Cogle, Christopher R. [3 ]
Garcia-Manero, Guillermo [4 ]
Grinblatt, David L. [5 ]
Komrokji, Rami [6 ]
Savona, Michael R. [7 ,8 ]
Scott, Bart L. [9 ]
Sekeres, Mikkael A. [10 ]
Steensma, David P. [11 ]
Flick, E. Dawn [12 ]
Kiselev, Pavel [13 ]
Louis, Chrystal U. [13 ]
Nifenecker, Melissa [13 ]
Swern, Arlene S. [13 ]
Foucar, Kathryn [14 ]
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] ARUP Labs, Salt Lake City, UT USA
[3] Univ Florida, Med, Gainesville, FL USA
[4] MD Anderson Canc Ctr, Houston, TX USA
[5] NorthShore Univ HealthSyst, Evanston, IL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[8] Vanderbilt Univ, Med Ctr, Program Canc Biol, Nashville, TN USA
[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[10] Cleveland Clin, Cleveland, OH 44106 USA
[11] Dana Farber Canc Inst, Boston, MA 02115 USA
[12] Celgene Corp, San Francisco, CA USA
[13] Celgene Corp, Summit, NJ USA
[14] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122913
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4747
引用
收藏
页数：4
相关论文
共 40 条
  • [21] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    BLOOD, 2014, 124 (21)
  • [22] Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization
    Xicoy, Blanca
    Jimenez, Maria-Jose
    Garcia, Olga
    Calabuig, Marisa
    Coll, Rosa
    Orna, Elisa
    Teresa Cedena, Maria
    Vicente, Ana
    Rivero, Eugenia
    Oiartzabal Ormategui, Itziar
    Zamora, Lurdes
    Hernandez, Jose-Angel
    Estrada, Natalia
    Callejas, Marta
    Gonzalez Gonzalez, Bernardo Javier
    de Paz, Raquel
    Cortes, Montserrat
    Palomo, Laura
    Bargay, Joan
    Villalobos, Maria-Lavinia
    Bailen, Alicia
    Montanes, Maria-Angeles
    Bernal Del Castillo, Teresa
    Lopez Cadenas, Felix
    Grau, Javier
    Brunet, Salut
    Jimenez, Ana
    Sanz, Guillermo
    Marco, Josefa
    Tzu Hua Chen-Liang
    BLOOD, 2018, 132
  • [23] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [24] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Verstovsek, S
    Cortes, J
    Ravandi-Kashani, F
    Beran, M
    Garcia-Manero, G
    Koller, C
    O'Brien, S
    Ferrajoli, A
    Estrov, Z
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 250A - 250A
  • [25] Impact of Transfusion Dependency on Health-Related Quality of Life Outcomes in Newly Diagnosed Patients with Myelodysplastic Syndromes (MDS). Analysis on 669 Patients By Disease Risk
    Efficace, Fabio
    Niscola, Pasquale
    Gaidano, Gianluca
    Ricco, Alessandra
    Caocci, Giovanni
    Breccia, Massimo
    Palumbo, Giuseppe A.
    Voso, Maria Teresa
    Vallisa, Daniele
    Allione, Bernardino
    Canicatti, Manuela
    Okumura, Iris
    Cottone, Francesco
    Invernizzi, Rosangela
    Bergamaschi, Micaela
    Borin, Lorenza Maria
    Di Tucci, Anna Angela
    Zhang, Huiyong
    Stauder, Reinhard
    Platzbecker, Uwe
    Luppi, Mario
    Petranovic, Duska
    Caers, Jo
    Cascavilla, Nicola
    Vignetti, Marco
    Mandelli, Franco
    BLOOD, 2017, 130
  • [26] Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis
    Iastrebner, Marcelo
    Zeidan, Amer M.
    Arbelbide, Jorge
    Rodrigues Pereira Velloso, Elvira Deolinda
    Pereira, Thales D. M.
    Boada, Matilde
    Crisp, Renee
    Hernan Pereyra, Patricio
    Reyes, Jheremy
    Helena Zappa, Maria
    Perez-Jacobo, Fernando
    Dela Pena Celaya, Jose Antonio
    Martinez Moreno, Emmanuel
    Abello, Virginia
    Elena Solano, Maria
    Cuervo, Diana
    Lorenzo Espinosa, Daniel
    Patricia Casas, Claudia
    Montoya, Leire
    Enrico, Alicia
    Prates, Virginia
    Apodaca Chavez, Elia Ixel
    Ontiveros-Austria, Juan
    Kornblihtt, Laura
    Gomez-De Leon, Andres
    Toledo, Victoria
    Negri, Luz
    Serrano, Juan
    Sanchez, Alexia
    Rodriguez-Zuniga, Ana Cecilia
    Stevenazzi, Mariana
    Goldschmidt, Valentina
    Grille, Sofia
    BLOOD, 2023, 142
  • [27] beta-2-microglobulin (B2M) is a significant prognostic factor for outcome of patients (pts) with newly diagnosed acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
    Cortes, J
    Kantarjian, H
    Keating, M
    OBrien, S
    Rodriguez, J
    Pierce, S
    Estey, E
    BLOOD, 1997, 90 (10) : 285 - 285
  • [28] First-Line (1L) Treatment Patterns and Outcomes Among Patients With Newly Diagnosed Myelodysplastic Syndromes (MDS): A Global, Retrospective Observational Cohort Study
    Symeonidis, Argiris
    Yucel, Aylin
    Deshpande, Gaurav A.
    Che, Min
    Gu, Tao
    Xiao, Hong
    Miteva, Dimana
    Nadal, Jose Alberto
    Le, T. Kim
    Butrym, Aleksandra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S353 - S353
  • [29] Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry.
    Erba, Harry Paul
    Pollyea, Daniel Aaron
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Seiter, Karen
    DeGutis, Irene
    Kiselev, Pavel
    McBride, Ali
    Yu, Edward
    Roboz, Gail J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes
    Patel, Jay L.
    Abedi, Mehrdad
    Cogle, Christopher R.
    Erba, Harry P.
    Foucar, Kathryn
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Komrokji, Rami S.
    Kurtin, Sandra E.
    Maciejewski, Jaroslaw P.
    Pollyea, Daniel A.
    Revicki, Dennis A.
    Roboz, Gail J.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Thompson, Michael A.
    Flick, Elizabeth Dawn
    Kiselev, Pavel
    Louis, Chrystal U.
    Nifenecker, Melissa
    Swern, Arlene S.
    George, Tracy, I
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (03) : 426 - 432
1234